Together, data gathered in pre-clinical and clinical studies suggest that Huperzine A has several key differentiating features:

• Multiple biologic activities that may impact Alzheimer’s disease and its symptoms, within a single therapy

• May exhibit significant neuroprotective activity, including anti-oxidant, anti-excito-toxic and anti-amyloid properties; animal studies indicate that Huperzine A pretreatment is protective against organophosphate-induced nerve cell death and can reduce glutamate-induced cell death

• Better penetration through the blood-brain-barrier, higher oral bioavailability and longer duration of AChE inhibitory action compared with other currently-available AChE inhibitors

• Peripheral cholinergic side effects (gastrointestinal) minimal and lower at therapeutic doses compared with other currently-available AChE inhibitors

• In both traditional medicine and pharmaceutical product forms, Huperzine A has already established a long track record of safety and efficacy in China